Command Palette

Search for a command to run...

Clinical Trials · NCT03325387

A Study of Multiple Doses of LY3305677 in Healthy Participants

CompletedPhase 1Mazdutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
56
Start date
Oct 2017
Locations
1 site, United Kingdom
Primary endpoint
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
View Mazdutide compound reference